1 April 2013 in Pharmacogenetics and Genomics
Background Earlier studies have demonstrated an association between N-acetyltransferase 2 (NAT2) catalytic activity and the genotype of a recently published tag single nucleotide polymorphism (SNP), rs1495741. There have been no reports on the relationship between the rs1495741 genotype and antituberculosis drug-induced hepatotoxicity (ATDIH) to date. Objective The aim of the present study was to determine the frequency of the NAT2 tag SNP (rs1495741) in the Taiwanese and its relation to the incidence of ATDIH. Materials and methods A total of 348 tuberculosis patients were enrolled to determine the frequency of NAT2 tag SNP rs1495741 and its relation to the incidence of ATDIH. The conventional NAT2 variants alleles have also been investigated. Furthermore, to evaluate the correlation of NAT2 activity and rs1495741 genotypes, a pharmacokinetic study of isoniazid was also conducted in healthy volunteers. Results Among the 348 tuberculosis patients, 20 (5.7%) were diagnosed with ATDIH. The frequencies of the three rs1495741 genotypes, viz., AA, AG, and GG, were 24.7, 52.3, and 23.0%, respectively. Significant differences among rs1495741 genotypes and susceptibility to hepatotoxicity were noted (odds ratio=14.068, P<0.05). Moreover, the rs1495741 genotypes showed an association with the isoniazid dosage required for induction of hepatotoxicity. In the pharmacokinetic study, NAT2 activity was strongly associated with genotype categories (P<0.001). Conclusion The present study demonstrated that the three genotypes according to rs1495741 were in good accordance with conventional NAT2 alleles-inferred phenotypes and the tag SNP could be used as a proxy to determine the susceptibility to ATDIH.
30 May 2017 in Analytical Methods
A simple and sensitive method for the determination of hesperidin and hesperetin was necessary for a pharmacokinetic (PK) study in Wistar rats. Polarity-switching mode was utilized to acquire positive ion electrospray data for hesperidin and neohesperidin dihydrochalcone-d3, and negative ionization data for hesperetin and rac-hesperetin-d3. The analytes were investigated in the multiple reaction monitoring mode as the precursor/product ion pair of m/z 611.2 → 303.1 for hesperidin, m/z 616.3 → 308.3 for neohesperidin dihydrochalcone-d3, m/z 301.3 → 164.1 for hesperetin, and m/z 304.3 → 164.1 for rac-hesperetin-d3. Hesperidin and hesperetin in rat plasma were separated with solid-phase extraction using a HyperSep Retain PEP column and separated on a Hypersil GOLD Phenyl reversed-phase column using a gradient elution of 0.1% formic acid in water and acetonitrile. Hesperidin was validated over the concentration range of 1–1000 ng mL−1, and hesperetin was validated over the range of 0.2–100 ng mL−1, both with r > 0.999. The respective within- and between-run precisions were 2.06–9.54% and 2.11–7.76%, and the within- and between-run accuracies were −6.52% to 3.82% and −1.62% to 2.33%, respectively, for both analytes. Extraction recoveries of these analytes were >87%. The matrix effects were between 94.7% and 113.6%. All of the analytes were stable during the assay and storage in Wistar rat plasma. The lower limit of quantification of the active metabolite hesperetin is up to 200 pg mL−1, so complete plasma concentration–time profiles can be obtained by the LC-MS/MS method without the need for enzymatic hydrolysis of the serum sample.
5 October 2015 in Archives of Toxicology
1 July 2013 in Current Drug Metabolism
Background & Aims: The incidence of isoniazid (INH)- and rifampicin (RIF)-induced abnormal liver enzyme activity is 27% but only 19% with INH alone. Cytochrome P450 2E1 (CYP2E1) is thought to contribute to the synergistic effects of RIF and INH. Pharmaceutical excipients are inactive ingredients that are added to a pharmaceutical compound. The purpose of this study was to screen excipients for CYP2E1 inhibition and identify whether the screened excipients prevented INH/RIF-induced hepatotoxicity. Methods: Fifty-five known pharmaceutical excipients were screened for CYP2E1 inhibition. The hepatotoxic doses of INH and RIF were 50 and 100 mg/kg/day, respectively. Hepatotoxicity was assessed by the galactose single point (GSP) method (a US Food and Drug Administration (FDA) recommended quantitative liver function test), liver histopathology, malondialdehyde (MDA) assay, and measurement of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity. We chose the CYP2E1-specific substrate chlorzoxazone to assess CYP2E1 activity in animal and human. Results: Mannitol inhibited CYP2E1 activity by 54% in mice with INH/RIF-induced hepatotoxicity (p < 0.005). Serum AST, ALT and GSP levels were significantly increased 3.8- to 7.8-fold in these mice (p < 0.005), and these levels could be lowered by mannitol. Mannitol significantly alleviated the depletion of hepatic glutathione (GSH) and partially reversed the increase in MDA formation in mice treated with INH/RIF (p < 0.005). Mannitol also decreased CYP2E1 activity by 58% in humans (p < 0.005). Furthermore, an antituberculosis (TB) efficacy assay revealed that mannitol did not affect the anti-TB effects of INH/RIF. Conclusions: Mannitol, an FDA-approved excipient, was found to be a CYP2E1 inhibitor. Mannitol may be a useful adjuvant for drugs that induce hepatotoxicity through CYP2E1, such as INH and RIF.
1 September 1997 in The Journal of Clinical Pharmacology
CHChristine Shu‐Hui Huang